MI/26/40 Postdoctoral Scientist

Key Details

Job ID:
MI/26/40
Role:
Postdoctoral Scientist
Salary:
£39,253 – £47,543 per annum (dependent upon qualifications and experience)
Closing date:
20th September 2025

About the role

We are seeking a Postdoctoral Fellow to work on two landmark studies of cancer evolution in kidney cancer: TRACERx Renal 300 (Tx300) and PEACE (Posthumous Evaluation of Advanced Cancer Environment). Together, these datasets span the full arc of ccRCC disease, from surgical resection of primary tumours through to the metastatic landscape captured postmortem and offer a rare opportunity to study kidney cancer evolution at an unprecedented depth and scale.

The project sits at the intersection of cancer biology and computational analysis. We are looking for someone with genuine biological curiosity and strong quantitative instincts. We value scientific judgement, a drive to understand cancer biology, and sufficient coding experience to work effectively with genomic datasets.

The Cancer Dynamics lab operates across the Cancer Research UK Manchester Institute and the Francis Crick Institute. The role will be based in Manchester with a visiting scientist status at the Crick taking advantage of both research communities.

About you

You should have a PhD in cancer biology molecular biology, genomics, bioinformatics or a related field along with a working knowledge of cancer genomics concepts: somatic mutation, copy number alteration, clonal evolution, phylogenetic reconstruction, tumour heterogeneity. You will have demonstrable experience of scripting in R and/or Python for biological data analysis and the ability to work with large multi-sample genomic datasets and navigate standard genomic file formats and tooling. Prior experience with cancer somatic genomic analyses (e.g. mutation calling, copy number, phylogenetics) would be an advantage.

Photograph of Professor Samra Turajlić
An immunofluorescence microscopy image of kidney tissue showing different tissue structures stained in red, blue, and green The blue colour (DAPI) is widespread, indicating the location of cell nuclei throughout the sample. The green colour (LTL) highlights specific regions, indicating the presence of proximal tubule cells. The red colour (NPHS1) is also distinct in certain areas, showing the presence of podocytes in the glomeruli. The overlapping colours in some regions suggest the complex structure and the close association of these different cell types within the kidney.
Paterson Building Scientific Administration

More information

Prof Samra Turajlić

Samra is the Director of Cancer Research UK Manchester Institute, a Consultant Medical Oncologist at the Christie and also leads the Cancer Dynamics research group. They apply evolutionary principles to predict the trajectory of individual cancers by studying the forces that shape cancer evolution with the aim of using this knowledge to improve patient outcomes.

Cancer Dynamics

One of the greatest challenges in cancer medicine is understanding and predicting the trajectory of individual cancers.rnrnAs a multi-disciplinary group of cancer geneticists, computational biologists and clinician scientists we are using methods from evolutionary biology to understand the variable natural history of individual cancers, and most critically the emergence of metastases and drug resistance.rnrnWe are applying evolutionary principles to the question by studying the forces that shape cancer evolution and use this knowledge to improve patient outcomes.rnrnWe are focusing on two cancers, renal cell carcinoma (RCC), which is the most common type of kidney tumour, and melanoma, the most aggressive type of skin cancer. RCC and melanoma exhibit a wide spectrum of clinical behaviour, some are indolent, others extremely aggressive and we want to know how this relates to their evolutionary trajectory.

About CRUK Manchester Institute

Our aim is to understand the fundamental basis of cancer and apply that knowledge to developing new treatment strategies for cancer patients. Our advanced research programmes span a spectrum of cancer research, from the molecular and cellular basis of cancer through to drug discovery, translational research and clinical trials. rnThe Institute has access to outstanding laboratory facilities and exceptional core services, including next generation sequencing, microarrays, confocal microscopy, bioinformatics, histology and mass-spectrometry.

Prof Samra Turajlić
Cancer Dynamics
About CRUK Manchester Institute

How to apply

To apply for this position please complete the online application via ‘Apply Now’. Please ensure you detail the names of three referees and ensure you submit your application before 20 September 2026.

For any informal enquiries about this post, please contact Prof Samra Turajlić: samra.turajllic@cruk.manchester.ac.uk

Please note this vacancy will close for applications at 18:00 hours on the closing date specified.

Contact us for further information

Why choose Cancer Research UK Manchester Institute?

The Cancer Research UK Manchester Institute, an Institute of The University of Manchester, is a world-leading centre for excellence in cancer research. The Institute is core funded by Cancer Research UK (www.cancerresearchuk.org),
the largest independent cancer research organisation in the world.

We are partnered with The Christie NHS Foundation Trust, one of the largest cancer treatment centres in Europe, which is located adjacent to the CRUK MI Manchester Institute in South Manchester. These factors combine to provide an exceptional environment in which to pursue basic, translational and clinical research programmes.

Careers that have a lasting impact on cancer research and patient care

We are always on the lookout for talented and motivated people to join us.  Whether your background is in biological or chemical sciences, mathematics or finance, computer science or logistics, use the links below to see roles across the Institute in our core facilities, operations teams, research groups, and studentships within our exceptional graduate programme.

Images of stained cells superimposed with headshot images of Samra Turajlic and Tim Somervaille
Image of skin cancer in ageing humans

Latest from CRUK MI

Cancer Research In the Paterson Building

Find out more about the facilities across the Institute

Two Institute Scientists elected to the Academy of Medical Sciences

We celebrate the recognition Professor Samra Turajlic and Professor Tim Somervaille by a prestigious medical science institution

New publication: Tissue-specific fibroblast lipid cues impose the rate of epithelial cancer invasion

Research explores the role of lipid signalling in cancer behaviour

Cancer Research In the Paterson Building
Two Institute Scientists elected to the Academy of Medical Sciences
New publication: Tissue-specific fibroblast lipid cues impose the rate of epithelial cancer invasion